ArriVent BioPharma Stock Plunges 63% After Lung Cancer Drug Misses Phase 3 Endpoint
ArriVent BioPharma shares fell 63% after its Phase 3 FURVENT trial missed its primary endpoint, highlighting binary biotech risk.
Option Care Health Surges 34% as McKesson and CD&R Agree to $5.8 Billion Takeover
Option Care Health jumped 34% after McKesson and CD&R agreed to a $5.8 billion takeover, highlighting ongoing US healthcare consolidation.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
ArriVent’s AVBP Plunges 60% After Lung Cancer Trial Misses Primary Endpoint
ArriVent shares plunged 60% after its lung-cancer trial missed the primary endpoint, despite dose-dependent response rat…
BridgeBio’s $BBIO Gains FDA Priority Review for Oral Infigratinib in Children With Achondroplasia
BridgeBio’s NDA for oral infigratinib received FDA acceptance and Priority Review, creating a closely watched regulatory…
Cenovus to Acquire Athabasca Oil in $5.7 Billion Cash-and-Stock Deal
Cenovus will acquire Athabasca Oil in a $5.7 billion cash-and-stock transaction, marking a major step in Canadian oil sa…
Vaxcyte Hits 52-Week High as Phase 3 Data Boosts VAX-31 Prospects
Vaxcyte reached a new 52-week high after positive topline Phase 3 OPUS-1 results strengthened the case for its VAX-31 va…
Alvotech Shares Jump 13.5% After FDA Clears AVT02 Manufacturing Changes
Alvotech’s $ALVO shares jumped 13.5% after FDA approval of AVT02 manufacturing changes, sharpening the focus on supply a…
Cenovus’s $5.7 Billion Athabasca Deal Reshapes Canadian Oil Sands Landscape
Cenovus’s $5.7 billion cash-and-stock Athabasca acquisition could accelerate oil sands consolidation and reshape investo…
Harrow Expands Ophthalmology Franchise With Completed TYRVAYA Acquisition
Harrow completed its TYRVAYA acquisition, adding the first and only FDA-approved nasal spray for dry eye disease to its …
GE HealthCare’s $945 Million Sofie Deal Signals Broader Radiopharmaceutical Push
GE HealthCare’s $945 million Sofie Biosciences acquisition could deepen its precision-imaging strategy while putting int…
Qiagen Shares Gain as Strategic-Buyer Talks Raise M&A Speculation
Qiagen shares gained after a report said talks with a strategic buyer had advanced, reviving questions about consolidati…